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Perinatal asphyxia resulting in neonatal encephalopathy (NE) remains one of the commonest 
causes of death and morbidity in term infants in low and middle income countries. The cause 
of NE frequently remains unknown and its clinical presentation unanticipated. Numerous 
researchers are looking for biomarkers to predict the development of NE. 
Aim  
The aim of this study was to determine the relationship between placental pathology in 
neonates with NE treated with therapeutic hypothermia (TH) at Tygerberg Hospital (TBH) 
Neonatal Intensive Care Unit (NICU) and their neurodevelopmental outcome.  
Methods 
Cases were derived from a prospectively collected database of 224 neonates ≥ 36 weeks 
with NE who underwent TH at TBH, between January 2010 and September 2014. The study 
sample comprised of 17 cases remaining once 23 deaths, 173 cases with no placental 
pathology and 11 cases with no neurodevelopmental assessment were excluded. Placental 
samples from high risk neonates delivering at TBH with no evidence of NE (n=30), were 
derived from a list of 1787 placental samples provided by the National Health Laboratory 
Service (NHLS) for comparison. All placentas were re-reviewed by an experienced 
pathologist and all neurodevelopmental assessments were done by a single specialist. 
Results 
Cerebral palsy (CP) occurred in 44% of the NE group. Villitis of unknown aetiology (VUE) 
was the single significant placental lesion associated with both neonatal encephalopathy 
(NE) (p=0.01) and CP (p=0.005) while chorioamnionitis, the commonest placental lesion in 
both groups, was not significantly different between the 2 groups. The survival to one year in 
the NE group was 89.9%. The placental pathology submission rate was only 13%. 
Conclusion 
As VUE was demonstrated to have a significant association with NE and CP, placental 
histopathology is an important predictor of neurodevelopmental outcome in neonates being 
treated for NE with therapeutic hypothermia. Improved placental submission needs attention. 
(Word count=298) 





Perinatale asfiksie wat neonatale ensefalopatie (NE) veroorsaak bly een van die algemeenste 
oorsake van dood en morbiditeit in voltydse neonate in lae en middel inkomste lande. Die 
oorsake van NE bly in menige gevalle onbekend en die kliniese voorkoms word dikwels nie 
voorsien nie. Vir die rede soek navorsers biomerkers wat die voorkoms van NE voorspel.  
 
Doel: 
Die doel van die studie is om die verwantskap tussen plasentale patologie in neonate met NE, 
wat behandel word met terapeutiese hipotermie (TH) in die Neonatale Intensiewe sorgeenheid, 
Tygerberg Hospitaal (TBH), en  neuro-ontwikkelings uitkoms te bepaal.  
 
Metodes: 
Die gevalle is gekies van ŉ prospektiewe versamelde databasis van 224 neonate ≥ 36 weke 
wat NE onderlêde het en TH ondergaan het tussen Januarie 2010 en September 2014. ŉ 
Groep van 17 gevalle het oorgebly nadat 23 sterftes, 173 gevalle sonder plasentale patologie 
en 11 gevalle sonder ŉ neuro-ontwikkelingsondersoek uitgesluit is. Neonate van hoë risiko 
swangerskappe met geen tekens van NE (n=30) is verkry van ŉ lys van 1787 plasentale 
monsters wat deur die Nasionale Gesondheid Laboratoriumdiens (NHLS) voorsien is. Al die 
plasentale monsters is herondersoek deur ŉ senior patoloog en al die neuro-
ontwikkelingsondersoeke is deur ŉ senior spesialis uitgevoer. 
 
Resultate: 
Serebrale verlamming (SV) het in 44% van die NE groep voorgekom. Villitis van onbekend 
oorsaak (VOO) was die enkel plasentale letsel wat geassosieer is met NE (p=0.01) en SV 
(p=0.005). Chorioamnionitis, die algemeenste plasentale patologie in beide groepe, het nie 
statisties verskil tussen die 2 groepe nie. Die een jaar oorlewing in die NE groep was 89.9%.  
Die proporsie van plasentas gestuur vir ondersoek was 13%.  
 
Gevolgtrekking: 
Omdat VOO ŉ betekenisse assosiasie het met NE en SV bevestig dit dat plasentale patologie 
ŉ belangrike voorspeller is van neuro-ontwikkeling in neonate wat vir NE deur middel van TH 
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List of Abbreviations 
 
• aEEG- Amplitude integrated electroencephalogram 
• BGT- Basal ganglia and thalami 
• CRF- Case recording form 
• C/S- Caesarean section 
• CTG- Cardiotocograph  
• ECM- Enterprise content management 
• HIE- Hypoxic ischaemic encephalopathy 
• HIV- Human Immunodeficiency Virus 
• HREC- Health Research Ethics Committee 
• MRI- Magnetic resonance imaging 
• MSL- Meconium stained liquor  
• MVM- Maternal vascular malperfusion 
• NE- Neonatal Encephalopathy 
• NHLS- National Health Laboratory Service  
• NICU- Neonatal Intensive Care Unit  
• NS- Not significant 
• NVD- Normal vertex delivery 
• PET- Pre-eclamptic toxaemia   
• PROM- Prolonged rupture of membranes 
• Rh- Rhesus 
• RPR- Rapid plasma reagin 
• SD- Standard Deviation 
• TBH- Tygerberg Hospital  
• TOP- Termination of pregnancy 
• VUE- Villitis of unknown aetiology 
  





• Cerebral Palsy - a non-progressive disorder of posture and movement caused by a 
defect or insult to the developing central nervous system 
• Chorioamnionitis – an inflammatory (maternal/foetal) response to microbial 
organisms in the amniotic fluid 
• Neonatal encephalopathy - a clinical syndrome characterized by altered 
neurological function in the early days of life in infants ≥ 35 weeks gestation 
• Neonatal mortality rate - the number of deaths in neonates less than 28 days of life 
per 1 000 live births in a given year or period. 
• Nulliparity- no previous deliveries 
• Perinatal asphyxia - impaired gas exchange leading to hypoxaemia, hypercapnia 
and a metabolic acidosis in a newborn 
• Perinatal mortality - the number of stillbirths and deaths in the first week of life per 
1,000 total births 
• Primigravida-first pregnancy 
• Prolonged second stage of labour- in primiparous women, three hours with an 
epidural or two hours without while in parous women two hours with an epidural and 
one hour without 
• Small placenta - placental weight < 10th centile for birth weight and gestational age 
• Therapeutic hypothermia - the core body temperature (measured by the 
oesophageal or rectal probe) is cooled down to 33.0–35°C for 72 hours 
 • Under five mortality - number of deaths between birth and exactly five years of age 
per 1,000 live births 
• Villitis of unknown aetiology – presumably an immune mediated maternal 
response at foetal antigens in the villous stroma  
 
 





Perinatal asphyxia is defined as a condition of impaired gas exchange that leads to 
hypoxaemia, hypercapnia and a metabolic acidosis.(1) While all foetuses experience asphyxia, 
those subjected to severe asphyxia are at a greater risk of developing neonatal 
encephalopathy (NE).(2) 
 
NE is a clinical syndrome characterized by altered neurological function in the early days of 
life in infants ≥ 35 weeks gestation. This includes an altered level of consciousness with or 
without seizures, depressed tone and reflexes and disturbances in maintaining respiration and 
feeding. In 1976 Sarnat and Sarnat developed a staging guideline for neonatal encephalopathy 
to stage the severity of neurological involvement. This guideline has been modified since then 
and is still in use today (Appendix A). (3) 
 
The Millennium Development Goals 2015 Report shows that worldwide neonatal mortality has 
dropped, between 1990 and 2015, from 33/1000 live births to 19/1000 live births. Of concern 
was that 24% of neonatal deaths still arise from complications during labour and delivery.(4)  
The global incidence of NE was estimated to be 1.15 million cases in 2010 with 85% of this 
occurring in low to middle income countries. Here the highest incidence of NE at 14.9/1000 
live births was in Sub-Saharan Africa.(5) On the contrary, the incidence of NE was 1.3/1000 live 
births in New Zealand(6) and moderate to severe hypoxic ischaemic encephalopathy (HIE), 
0.37/1000 live births in Japan .(7) 
 
Perinatal asphyxia remains one of the commonest causes of death and morbidity in term 
infants in low and middle income countries. In a retrospective study looking at the outcome of 
neonates treated at Charlotte Maxeke Academic Hospital in Gauteng over a 5 year period, the 
incidence of perinatal asphyxia was calculated  to be 4.7/1000 live births/year.(8) Similarly in a 
study conducted in the Southern Cape Peninsula the incidence of HIE ranged from 2.3-
4.3/1000 live births and the incidence varied according to the criteria used to define birth 
asphyxia and HIE.(9) In contrast to this a higher incidence of birth asphyxia and HIE was 
reported from Chris Hani Baragwanath Hospital in 2011. The incidence of birth asphyxia was 
8.7-15.2/1000 live births and HIE 8.5-13.3/ 1000 live births.(10) 
 
The burden of disease lies in those who survive with varying degrees of long term disability, 
with a survival rate of 86.7% found in a South African study at a tertiary academic centre 
looking at the outcomes of neonates with perinatal asphyxia.(8) 
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Until recently there were limited successful therapeutic interventions available to treat 
neonates with neonatal encephalopathy. Mild therapeutic hypothermia (TH) in infants with 
moderate encephalopathy if started within the first six hours of life has shown promise in 
studies done in both developing and developed countries to decrease mortality and long-term 
severe neurodevelopmental disabilities.(11)(12) 
 
As the cause of NE is frequently unknown and its clinical presentation unanticipated various 
researchers are looking for biomarkers to understand the development of NE. It has been 
postulated that placental histology may give clues as to the cause of the encephalopathy. The 
placental pathology may also provide an aid to risk assessment for an abnormal neurological 
outcome. The placenta can also provide information prompting urgent care for both mother 
and baby. There have been numerous studies performed in high income countries correlating 
placental pathology and the outcome from neonatal encephalopathy. Badawi et al found that 
a placenta with abnormal findings doubled the risk of developing neonatal encephalopathy.(13) 
This finding was supported by a study examining the placentas from 125 neonates ≥ 36 weeks 
gestation from a medicolegal registry who had NE and subsequently developed cerebral palsy 
(CP) or long-term neurological impairment. The authors compared the findings of the placentas 
to the placentas of 250 consecutive singleton deliveries at >36 weeks without neurological 
impairment. Severe foetal vascular lesions were found in more than half of placentas from 
index cases but were present in only 10% of the control group. This amounts to a 5 fold  
increase in the risk of developing neonatal encephalopathy if abnormal placental lesions are 
present (p<0.0001).(14) Similarly, in a study of 40 placentas in a medico-legal review of 
neonates with neurological impairment compared to the placentas from neonates with 
meconium stained liquor with no neurological impairment, severe foetal chorioamnionitis, 
extensive avascular villi and diffuse chorioamnionic haemosiderosis were found to be 
independently associated with NE. The risk of NE increased as the number of placental lesions 
increased. (15) 
 
Hayes et al., also looked at placental changes, the grade of NE and long-term neurological 
outcome in infants >36 weeks gestation who had NE and underwent TH in their unit. In a study 
of 245 infants with NE in which only 141 placentas were sent for pathology, and 8 were 
excluded due to incomplete notes, 15 deaths and 13 cases of cerebral palsy were reported. 
The study reported that placental haemorrhage at any site, was associated with NE across all 
grades of severity. Meconium and haemorrhagic placental changes had a significant impact 
on the infants’ neurodevelopmental outcome. An additional finding in the study was that a 
higher placenta to birth weight ratio was associated more significantly with grade 1 and 2 NE. 
Infection/inflammation was found to be associated with a low grade encephalopathy while 
villitis and funisitis with a higher grade of encephalopathy.  As the number of lesions increased, 
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the neurodevelopmental outcome worsened. Surprisingly, there was no relationship between 
placental lesions and specific patterns of brain injury on Magnetic Resonance Imaging 
(MRI).(16)  
 
More recently, Mir et al., looked at placental pathology in neonates requiring TH and the 
association of NE within the first six hours of life and more long-term adverse 
neurodevelopmental outcomes(17)  An abnormal neurodevelopmental outcome was defined as 
death or a Bailey-III Score <85.(18) Placental abnormalities were present in 95% of cases, with 
65% of cases meeting the criteria for major placental pathology. Placental pathology findings 
increased as the severity of NE increased (P<0.001), with chorioamnionitis being present in 
54% of cases. Chronic patchy villitis/diffuse villitis was the single placental finding significantly 
associated with an abnormal neurological outcome. Placental villitis was identified in 13 
neonates, 92% of these neonates had an abnormal neurological outcome. Five of these 
neonates demised, the survivors had severe delays with a Bailey III score < 70.(17)   
 
In a systematic review of papers, over an 18 year period, looking at placental pathology and 
related neonatal outcome and neurological development, both foetal thrombotic vasculopathy 
and funisitis were found to be associated with neonatal encephalopathy. A weakness of this 
review was that it excluded studies done in developing countries. There might also have been 
publication bias towards the correlation between placental pathology and neonatal 
encephalopathy in highly developed countries. (19) 
 
How these findings relate to neonatal encephalopathy in neonates born in middle and low 
income countries remains uncertain as all of these studies were done in highly developed 
countries. 
 
In 2000 only 6 placentas were submitted for histology at TBH. By 2004, the submission rate 
had improved, an audit done over a 25 month period yielded 848 placentas accounting for 
15% of all deliveries. This audit compared the proposed clinical diagnosis to the 
histopathological diagnosis. Where there was an adverse pregnancy outcome without a clinical 
cause, histopathology in most cases revealed acute chorioamnionitis or uteroplacental 
insufficiency or both. Thirty placentas were submitted for suspected intrapartum hypoxia or 
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2 Study Justification 
 
2.1 Gaps in the Literature 
 
Sub-Saharan Africa carries a large portion of the global burden of under-five mortality, perinatal 
mortality and NE yet there is very little data on NE, the factors associated with possible causes 
of NE and how these factors might influence the long-term outcome of these neonates treated 
with TH. Most research on this aspect of neonatal care has been performed in high income 
countries. The research from middle and low income countries has mostly focused on the 
incidence and mortality associated with perinatal asphyxia. Furthermore, the study design of 
research studies on the long-term outcome of neonatal encephalopathy has limitations which 
make the data of limited value to neonates being cared for in middle and low income countries. 
These limitations are further complicated by the disease profiles that commonly occur in middle 
and low income countries which include HIV and puerperal sepsis, syphilis and tuberculosis. 
The incidence of maternal malnutrition, chorioamnionitis and pre-eclamptic toxaemia (PET) is 
also higher in low and middle income countries. All these factors could influence placental 
function and therefore might be responsible for the high incidence of neonatal encephalopathy 
in low and middle income countries. The developing world also struggles with poorer obstetric 
care, a greater incidence of obstructed labour, lack of skilled personnel and basic equipment 
for resuscitation and Neonatal Intensive Care Units (NICU’s) with ventilator capacity. 
 
Therefore, a study is required to address some of the gaps in the literature concerning neonatal 
encephalopathy in low and middle income countries. This study is designed to attempt to fill 
the knowledge gap in the association of placental pathology with severe neonatal 
encephalopathy 
 
2.2 Null Hypothesis 
That neonates with perinatal asphyxia have normal placental pathology. 
 
2.3 Problem statement 
Neonates with NE treated with TH, as compared to non-NE neonates, the neurodevelopmental 
outcome is associated with placental pathology findings. 
 
2.4 Research Question  
In neonates with NE treated with TH, when compared to non-NE neonates, is the neurological 
outcome associated with placental pathology findings? 
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2.5 Study Aim  
We aim to study the relationship between placental pathology and the neurological outcome 
in infants with NE treated with TH. 
 
2.6 Primary Outcomes 
 Describe placental pathology findings in our NE and non-NE groups. 
 Describe an association between placental findings and clinical outcomes in patients with 
NE. 
 
2.7 Secondary outcomes 
 Correlate placental pathology findings with MRI findings in those infants that were 
scanned. 
 Describe findings that may be predictive of possible recurrence and could guide care in 
subsequent pregnancies. 
3 Materials and Methodology 
3.1 Study Design 
This is a descriptive study of infants with NE treated with TH at Tygerberg Hospital (TBH) NICU 
from January 2010 and September 2014. Due to the anticipated small yield we propose that 
this be a pilot study. 
 
3.2 Study Site 
Tygerberg Children’s Hospital forms part of the larger TBH. It services the immediate 
surrounding areas and provides tertiary care to the Metro East and the more rural Northern 
and Eastern regions of the Western Cape. Neonates with NE who qualify for TH are treated in 
the NICU. The NICU is an 8 bedded intensive care unit with an additional 4 high care beds 
which are also sometimes used for TH if there are no NICU beds available. The NICU provides 
care to 506 neonates/year (2015). 
 
Once discharged these infants are followed up at a high risk baby clinic based in the community 
or a neonatal clinic at TBH. They also receive a follow up appointment for a 12-15 week 
assessment by a neurodevelopmental specialist at a high risk clinic situated in the outpatient 
clinic block of TBH. They are then followed up to 1 year of age. 
 
3.3 Study period 
The study was conducted from January 2010 to September 2014. 
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3.4 Study population 
3.4.1 The NE group 
There is an existing database of all neonates with NE who undergo TH in our NICU at TBH, 
we accessed this database between January 2010 and September 2014, and it comprised 224 





3.4.2 The non-NE group 
A comparative group of non-NE patients were selected from a database provided by the NHLS, 
which comprised of a list of 1787 placental samples submitted during the study period for 
various indications (miscarriages, stillbirths, intrauterine deaths, molar pregnancies, premature 
deliveries, maternal illness, suspected congenital infection, suspected chorioamnionitis, twin 
pregnancies and NE). From this list neonates of 36 weeks gestation with no signs of 
encephalopathy were extracted. This was determined by reviewing the Apgar scores (7 at 5 
minutes), documentation on routine clinical examination following C/S deliveries, birth records, 
nursing and medical notes where infants were admitted. Exclusion criteria were: infants <36 
weeks gestation, twins with fused placental plates, placental histopathology not available, 




1. ≥36 week’s gestation 
2. NE & underwent TH at TBH 
3. Neurodevelopmental follow up  
4. Placental histology available 
5. Survival to 1 year of life 
6. Absence of congenital anomaly 
 
 
Figure 3-1 Inclusion criteria for NE group. Abbreviations: NE= neonatal 
encephalopathy, TH= therapeutic hypothermia, TBH= Tygerberg Hospital 
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3.5  Data Collection 
From the database of all neonates who underwent TH during our study period at TBH and the 
list of placentas we were able we were able to identify those patients who were cooled and 
also had a placenta sent for histology. 
 
We then accessed Enterprise Content Management (ECM) for electronic records, patient 
folders from medical records at TBH, cooling booklets which are routinely collected data on all 
patients who are cooled our hospital setting and Clinicom, the hospitals electronic database 
which tracks admission status, previous admissions or clinic visits attended. This enabled us 
to determine if patients had attended neurodevelopmental follow up at the TBH high risk clinic. 
Clinical data collection comprised a folder review of notes found on ECM, accessing the cooling 
data booklets used for routine monitoring of cooled patients and folder reviews at our Records 
Department. 
Clinical data from the non-NE group was also sourced from ECM.  
 
3.5.1 Patient data collected for NE group 
 Maternal data: age, gravidity and parity, maternal illness, booking bloods: Rapid plasma 
reagin (RPR)/ Rhesus (Rh)/Human Immunodeficiency Virus (HIV) 
 Delivery data: prolonged rupture of membranes (PROM), meconium stained liquor (MSL), 
abnormal cardiotocograph (CTG), mode of delivery, inborn/out born 
 Patient data: gestational age (GA), birth weight (BW), sex, Apgar score, head 
circumference (HC), length, blood gas analysis within one hour of life  
 Data in the postnatal period: HIE score and grade according to the Thompson score(22) 
(Appendix C) where HIE grade 1 ≤10; HIE grade 2=11-14; HIE grade 3 ≥15, were done 
within the first 6 hours and then at least daily. Seizures, amplitude integrated 
electroencephalogram (aEEG) findings, need for ventilation and inotropic support, 
evidence/proven infection.  A proven infection was defined by the gold standard, a 
positive blood culture, while evidence of infection was defined as a CRP value above 
10mg/ml. 
 Placental factors: placental weight, placental histopathology findings 
 Imaging: MRI if available 
 Neurodevelopmental outcome was assessed using the Bayley Scales of Infant and 
Toddler Development, 3rd Edition, screening tool and this by done by a single specialist. 
A score of less than 70 was abnormal while below 85 was deemed suspect and required 
further follow up.   
 Mortality 
  
Stellenbosch University  https://scholar.sun.ac.za
16 
 
3.5.2. Patient data collected for the non-NE group 
 Maternal data: age, gravidity and parity, booking bloods RPR/Rh/HIV, maternal illness 
 Delivery data: PROM, MSL, Abnormal CTG, mode of delivery, inborn/out born 
 Patient factors: GA, BW, sex, Apgar score, HC, length, blood gas analysis within one 
hour of life if available, reason for admission if admitted  
 Placental factors: placental weight, placental histopathology report 
 
The Department of Anatomical Pathology re-reviewed the placental pathology of both groups. 
The re-review was carried out by an experienced anatomical pathologist (PS) who was blinded 
to the neurological outcome. Placental examination findings were recorded using a 
modification of the Amsterdam Criteria,(23) The TBH Department of Anatomical Pathology 
Placenta Cluster Diagnosis Expanded Version (Appendix C). All infants in the NE group were 
examined using the Bayley Scales of Infant and Toddler Development, 3rd edition screening 
tool, at 12 months by a single examiner (JVZ) with experience in neurodevelopmental 
assessments and were classified as having normal, suspect or abnormal neurology. 
 
3.6. Data management: 
The data was collected on case recording form (CRF) using a patient study number only and 
then transcribed onto an electronic database (Excel) with this patient study number.  
Data was handled in accordance with the Good Clinical Practice requirements. A laptop in a 
locked office was used to store the database which was password protected. Analysis and 
calculations were done from copies. All paper based documents will be kept in a locked 
cupboard for 5 years. 
 
3.7. Data analysis:  
A statistician was enlisted to assist with analysis of data. The results were fed back to the 
researcher, values where then further analysed. 
 
3.8. Statistical Methods  
The two sided Fisher’s Exact test was used to test the null hypothesis. 
Categorical variables were reported as number and percentages. 
Continuous variables were reported as means and standard deviation. 
 
3.9. Ethical Considerations 
This protocol was submitted to the Stellenbosch University Health Research Ethics Committee 
for ethics approval (approval number S16/04/064). 
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This is a retrospective review of routinely collected data and a waiver of individual informed 
consent was granted by the HREC and Hospital Management. 
 
Patients were allocated study numbers, and the results will be presented/published in an 
anonymous fashion. There were no undue investigations imposed on the study population, no 
infringement on personal time for questionnaires or travel to hospital for investigations. The 
care given to patients was in no way influenced by this study. This study will also bring no 
benefit or harm to this group of patients. 
 
As described earlier the burden of HIE in our setting is huge with great cost to the families of 
those who demise and survive. Survivors are often disabled and mostly rely on our over-
burdened health care system. Facilities for children who are disabled and access to these 
facilities vary greatly from region to region. 
 
We aim to investigate the issue of perinatal–related HIE which has not been adequately 
reviewed in Africa before. It is our hope that by reviewing and assessing maternal and 
antenatal factors, placental histology characteristics and neurological outcomes we can 
identify modifiable factors which can assist in reducing the incidence, morbidity and mortality 
associated with this debilitating condition and  that our findings will benefit future generations 
and lessen the burden of HIE. 
4 Results 
4.1 The group with NE  
During the study period 224 neonates with NE underwent cooling. There were a total of 23 
deaths in this group when followed up until one year of life, resulting in a survival rate of 89.8% 
(n=201) (Figure 4.1). Of the remaining 201 cases, only 28 (13.9%) placentas were submitted 
for histology. A further 11 cases were excluded in the NE group as there was no 
neurodevelopmental assessment. 
  






4.2 The non- NE group 
From the list provided by the NHLS, 1107 were screened before we met the target of 34 non- 
NE neonates, however once the placentas were reviewed a further 4 cases were excluded, as 
there were two sets of twins where there was a single placental plate.  
 
4.3 Demographics and baseline characteristics 
The demographics of our 2 groups are depicted in Table 4.1. There were significant differences 
in mean gestational age (p=0.005), mean birthweight (p=0.003), male sex (p=0.01), mean 
parity (p=0.01) and head circumference (p<0.0001).  
Small for gestational age (SGA) was not a significant (p=0.3) finding. The mean parity was 1.2 
in the NE group and 1.9 in the Non-NE group (p=0.01). The maternal illnesses which we looked 
at included hypertension, HIV and diabetes (p=0.3) and there were no significant (NS) 





•23 excluded as 
death before 1 
year 
201 survivors 
• 173 excluded as no 






•11 excluded as no 
neurodevelopmental 
follow up 
Figure 4-1 The recruitment of the patients enrolled in the study. TH= therapeutic hypothermia 




Demographics NE group Non-NE group P value 
 n % n % P 
Total 17  30   
Inborn 8  47 30  100 <0.0001 
Male 14 82 13 45 0.01 
Mean BW (grams) 3209(406)  2780(465)  0.003 
Mean Gestational Age (weeks) 39.5(1.5)  38(1.8)  0.005 








Mean maternal age (years) 24.1  26.2  0.3 
Mean parity 1.2  1.9  0.01 
Maternal HIV positive 2 11.8 8 26.7 0.7 
Maternal hypertension 5  29 12 40 0.5 
Table 4-1 : Description of the demographics and baseline characteristics of NE and non-NE groups. 
Where indicated values are a mean (±SD) or n (%). # Data not available due to incomplete notes. 
Abbreviations: NE= neonatal encephalopathy, BW= birth weight, HIV= human immunodeficiency 
Virus 
 
4.4 Labour and delivery 
The only significant finding during labour and delivery was the presence of a prolonged second 
stage (P<0.0001) as documented in the clinical notes. There was no significant difference 
between the two groups in the mode of delivery, although C/S approached significance 
(P=0.06). 
 
4.5 Birth and the postnatal period 
During the immediate postnatal period (IPP) 69% (n=13) of the NE group had a time to 
spontaneous respiration of ≥ 5 minutes. During the IPP the mean pH and mean Apgar score 
were significantly different when comparing the 2 groups (p<0.0001). Ten (59%) neonates in 
the NE group required ventilation with one needing inotropic support. The majority of infants 
treated with TH were scored as grade 2 NE (47%), followed by 6 (35%) with Grade 1 NE and 
3 (18%) with Grade 3 NE. Twelve (71%) neonates in the NE group developed seizures, clinical 
or electrical (P<0.0001) and met our crititeria for presumed sepsis (p-value=0.0004). 
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Of those 12 neonates who had seizures, 11 were also in the sub-group with presumed sepsis 
and 9 had a lumbar puncture, with no CSF sample meeting the criteria for bacterial or viral 
meningitis. 
 
Nine (30%) neonates in the non- NE group were admitted in the nursery. There were 3 (10%) 
cases of transient tachypnoea of the newborn, with one based on clinical grounds and 2 on 
CXR changes. 6 (20%) patients were admitted with suspected sepsis; none had positive blood 
cultures, 5 neonates had a raised C-reactive protein (CRP) and one had neither. (Table 4.2) 
  




Labour, delivery& postnatal period 
NE group 
N=17 
No NE group 
N=30 
P-value 
 n % n % P 








MSL 7 41 5 17 0.08 
PROM 3 18 3 10 0.6 
Delayed 2nd stage 9 53 0 0 <0.0001 
NVD 8 47 3 20 0.09 
C/S 8 47 23 76.7 0.06 
Assisted delivery 1 5.8 1 3.3 1.0 
Apgar at 1 min 3.1(1.36)  7.4(1.47)  <0.0001 



































75 6 20 0.0004 
Seizures 12 71 0 0 <0.0001 
Table 4-2 : Labour, delivery, and the post-natal period. Where indicated values are a mean (±SD) or 
n (%). Abbreviations: NE= Neonatal Encephalopathy, CTG= cardiotocograph, NVD= normal vertex 
delivery, C/S= caesarean section, BE= base deficit, PROM= prolonged rupture of membranes, MSL= 
meconium stained liquor. #Data not available due to incomplete notes. †Data incomplete as not 
routinely collected in this group of patients 
 
4.6 Neurodevelopmental follow up and outcome 
Sixteen (94%) of those in the NE group had a neurodevelopmental assessment at 12 months. 
Seven (44 %) infants had a normal examination at 12 months, while 9 (56%) infants had an 
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abnormal neurological assessment. Of those with an abnormal examination:  7 (78%) had CP, 
1 (11%) had an isolated fine motor delay and 1 (11%) an isolated speech delay. Only one 
patient in the NE group did not have a 12 month neurodevelopmental assessment but this 




 Neurological assessment in NE group (n=16) 
 n % 
Normal examination 7 44 
Abnormal neurology 9 56 
 Cerebral Palsy 7/9 [78] 
 Speech delay 1/9 [11] 
 Fine motor delay 1/9 [11] 
Table 4-3 : 12 month neurodevelopmental outcome.  
 
4.7 Placental pathology 
Sixteen (53.3%) of placentas submitted in the non-NE group where in patients with a clinical 
suspicion of chorioamnionitis, 10 (33%) in twin pregnancies, 2 (6.7%) in suspected congenital 
infection, 1 (3.3%) maternal TB and 1 (3.3%) patient where a C/S was done for foetal distress. 
The neonate, however, had no features of NE and was discharged to the mother post-delivery. 
 
Significantly more of the placentas in the NE group (24%) had villitis of unknown aetiology 
(VUE) when compared to the placentas in the non- NE group, in which not a single case of 
VUE was described (p=0.01). 
 
There was no significant difference when comparing chorioamnionitis (p=0.5), mean placental 
weight (p=0.5) or number of placental lesions (p=1.0) between the 2 groups. (Table 4.4) 
  




Placental Characteristics NE group (N=17) Non- NE group (N=30) P-value 
 n % n % P 
Placental weight (grams) 499.06 (122.5)  472.97 (131.34)  0.5 
PW:BW 0.156 (0.033)  0.171 (0.045)  0.3 
 Chorioamnionitis 7 41 16 53 0.5 
 maternal response only 0 0 4 13 0.3 
 maternal and foetal response 7 41 12 40 0.3 
 severe foetal response 5 29 10 33 1.0 
VUE 4  24 0 0 0.01 
Subacute foetal hypoxia with 
compensatory response 
3 18 9 30 0.5 
 -focal villous oedema 1 5.8 2 6.7 1.0 
 -chorangiosis 0 0 5 16 0.1 
 -increased nucleated red 
blood cells 
3 18 4 13 0.7 
Small placenta  3  18 3 10 0.7 
Complete MVM 0 0 0 0  
Some Features of MVM      
 small placenta 5 29 12 40 0.5 
 Accelerated villous 
maturation 
0 0 1 3.3 1.0 
 Retroplacental haemorrhage 1 5.8 3 10 1.0 
 increased syncytial knots 0 0 1 3.3 1.0 
Features of FVM 0 0 0 0  
Chorioamnionic Haemosiderosis 0 0 0 0  
Haematogenous infection 0 0 0 0  
Presence of meconium laden 
macrophages 
3 18 6  20 1.0 
Normal placenta 0 0 6  20 0.07 
Multiple placental lesions 9 56 16  53 1.0 
Table 4-4 Placental pathology and characteristics in the NE and non-NE groups. Where indicated 
values are a mean (±SD) or n (%) Abbreviations: NE= neonatal encephalopathy, VUE= Villitis of 
unknown aetiology, PW= placental weight, BW= birth weight, MVM= maternal vascular 
malperfusion, FVM=foetal vascular malperfusion. 
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When comparing the severity of chorioamnionitis there was no significant difference between 
the 2 groups, with a severe foetal response present in 5 (29%) of the NE group and 10 (33%) 
of the non-NE group. 
 
When assessing the association with placental lesions in the subgroup with abnormal 
neurology, all cases of CP (n=7) had either a diagnosis of VUE, chorioamnionitis or a small 
placenta (Table 7). Only one case of CP was associated with more than one placental lesion. 
The one infant who had an isolated speech delay had a placenta that met the criteria for 
chorioamnionitis, and the one infant who had isolated fine motor delay had placental changes 
meeting criteria for a small placenta.(Table 4.5) 
 
Table 4-5 
Placental Lesions In CP (n=7) No of cases P-Value 
VUE 3 0.005 
Chorioamnionitis 2 0.4 
Small placenta 1 0.4 
Small placenta + chorioamnionitis 1 0.2 
Table 4-5 : Placental lesions found in cases of cerebral Palsy.  
Abbreviations: VUE = villitis of unknown aetiology, CP = cerebral palsy 
 
4.8. MRI 
MRI scans were only performed in five (29%) of the NE group and 4 of those who were imaged 
went on to develop CP. The findings are summarized in table below describing the placental 
pathology, the CP sub-type and MRI findings if available.(Table 4.6) 
 
Table 4.6 
Patient Cerebral Palsy type MRI findings Placental pathology 
1.  Dystonic Left caudothalamic 
haemorrhage 
VUE 
2.  Spastic diplegia  Leukoencephalopathy VUE 
3.  Dystonic  Global white matter 
loss 
 Chorioamnionitis 
 Small placenta 
 Meconium laden 
macrophages 
4.  Spastic quadriplegia Encephalomalacia Chorioamnionitis 
Table 4-6 : Description of CP sub-type, MRI findings and placental lesions. Abbreviations: 
CP=Cerebral Palsy, MRI=magnetic resonance imaging, VUE=villitis of unknown aetiology  
  





In this study examining the association between the neurodevelopmental outcome of neonates 
with neonatal encephalopathy (NE) and placental pathology, the primary outcome of the study 
demonstrated a significant association between villitis of unknown origin (VUE) and  NE (p= 
0.01) and CP (p=0.005) at 12 months. The calculated proportion of placentas submitted for 
histopathology in neonates with NE was 13%.  
 
VUE is postulated to be a non-infectious, immune mediated process characterized by a 
maternal lymphocytic response within foetal vascular structures. VUE more commonly occurs 
in term pregnancies, being present in 5-15% of all placentas at term with the majority of these 
pregnancies having a normal outcome.(24) The recurrence rate is high, with up to 37% in one 
study reporting VUE in subsequent pregnancies.(25) VUE has been found to be significantly 
associated with neonatal encephalopathy(16) and high grade VUE with an abnormal 
neurodevelopmental outcome (14)(17) which is similar to the findings of this study. A 2016 Dutch 
study reported that there was no association between VUE and a poor neurodevelopmental 
outcome but in this study population there were no cases of CP.(26)  Although there have been 
no previous reports of low grade VUE and a poor neurodevelopmental outcome, in this study 
one of our cases with low grade VUE developed CP. While the association was not statically 
significant and it is acknowledged that the development of CP is multifactorial, further studies 
are required to look into the association of low grade VUE and CP.  
 
The most common lesion in both the NE and the non-NE groups was chorioamnionitis, 
although there was not a statistical difference in chorioamnionitis between the 2 groups 
(p=0.5). Chorioamnionitis is recognized as a risk factor for cerebral palsy, specifically spastic 
quadriplegia in term and near term deliveries.(27) It is thought that a foetal inflammatory 
response leads to the production of pro-inflammatory cytokines and that this results in many 
sequelae including brain injury. (28) Chorioamnionitis was common in most studies reviewed, 
with varying significance. Similar to findings in our study, a 2016 Dutch study found no 
significant association between chorioamnionitis and an abnormal neurological outcome.(26) 
Two different studies by Redline showed that severe foetal chorioamnionitis [15] and 
chorioamnionitis [14] were significantly associated with neurological impairment. This was 
supported by studies by Mir et al. and Hayes et al., who found chorioamnionitis  to be a 
significant precursor in NE [17] (specifically grade 1 NE)  and funistis to be associated with grade 
3 NE. [16] The findings demonstrating the association between chorioamnionitis and NE as 
reported by Redline(14)(15) might reflect a sampling bias as the cases in their 2 studies originate 
from a medicolegal review. These 2 studies also did not include neonates managed with TH 
Stellenbosch University  https://scholar.sun.ac.za
26 
 
which has been shown to decrease mortality and long term neurodevelopmental impairment 
in moderate NE.(11)(12)(14)(15) 
 
NE is widely accepted as an indication for placental submission for histopathological 
examination to investigate possible causes of NE. (29) The rate of placental submission in this 
study was 13% in the group with NE. This finding is similar to the 2004 general submission 
rate of 15% at TBH, whereas four years prior to this (in 2000) only 6 placentas were submitted 
the entire year.(20)(21) Internationally, submission rates varied between 4.9% in a 2011 study in 
Yemen (30) and 81.8% in an American study in 2010.(31)  The poor submission rates in Yemen 
were ascribed to a number of reasons, namely: (1) lack of hospital guidelines (2) College of 
American Pathologists (CAP) guidelines not in place (3) decision for placental submission lying 
with the attending doctor (4) poor communication between clinicians & pathologists (5) failure 
to recognize the benefit of submitting placentas and (6) lack of understanding of pathology 
terms. (30) The success in the American study is attributed to adoption of the CAP guidelines, 
and consideration of whether placental submission is necessary in each delivery.(31) Although 
the obstetric and neonatal services at TBH use criteria for placental submission which have 
been established and agreed upon by obstetricians, pathologists and neonatologists these 
guidelines are clearly not adhered to. (20) The importance of submitting the placentas for 
histopathology is demonstrated by the fact that all of the placentas in the sub-group with CP 
had some histopathological abnormality. This is similar to Mir et al’s findings, with 95% of NE 
cases having some histological abnormality(17)  and Hayes et al finding a placental lesion in 
92.3% of their CP cases.(16)   
 
The only significant finding relating to delivery was a delayed second stage in the NE group 
(p<0.0001), with C/S in the no NE group approaching significance (p=0.06). This is in contrast 
to the literature reviewed, where emergency C/S was found to be a significant factor in those 
with brain injury on MRI (32) and across all grades of encephalopathy (16) . An Apgar score of < 
7 at 5 minutes in the NE group was significantly different when compared to the non-NE group 
in this study (P<0.0001), similar to findings by Redline (14)(15) and those of Mir who found lower 
median 5 min Apgar scores of 5 in the group with moderate to severe NE.(17) Ph in the NE 
group was also significantly lower (p<0.0001), similar to findings by Mir et al where pH differed 
significantly between mild and moderate to severe cases of NE. (17) 
 
Demographics which were of significance in NE included a greater birth weight (p=0.003), 
gestational age (p=0.005), head circumference (p<0.0001) and greater proportion of male 
infants (p=0.01), while mothers were more likely to be primigravida (p=0.01). Some studies 
reviewed also found birthweight(14) , gestational age(14)(16)(17) and primiparity(14) to be associated 
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with NE, with primiparity significantly associated with an abnormal neurodevelopmental 
outcome.(26) 
 
Markers of inflammation were reviewed and a raised CRP was statistically significant in those 
with NE (p=0.004). This is problematic since the gold standard for sepsis is a positive blood 
culture and the CRP increase may be a consequence of therapeutic hypothermia(33) or 
represent a systemic inflammatory response in those with severe NE.(34) 
 
Survival to one year in the NE group was 89.9%, while most studies commented on survival in 
the neonatal period or to discharge, reporting 86.7% in another South African study (8) and 93% 
(17) , 89%(16)  and 83%(14) in other studies reviewed. Sixteen of the NE group had a 12 month 
neurodevelopmental assessment, with 7(43%) subsequently diagnosed with CP. The high 
incidence of CP in our group was similar to the 43% in a study by Redline(14), while Hayes 
found CP in 13.7% (16) of her study population. The findings in Redline’s study could result from 
these cases originating from a medicolegal review and the absence of TH as a therapeutic 
measure in that study.  
 
MRI imaging is not routine in all cases of NE at TBH and too few studies were done to 
demonstrate the significance of this investigation. Significant associations in the literature 
include VUE and brain injury, specifically injury of the basal ganglia and thalami (BGT)(26) or 
hemispheric devastation/white matter injury.(17) Although chorioamnionitis was a common 
finding in those with no evidence of brain injury and those with the most extensive injuries, 
there was no significant difference between groups.(32)  Similarly, Hayes et al found no 
significant associations with chorioamnionitis but numbers in that study were small. (16) 
 
The strengths of this study lie in it being unique in the African setting, as we have limited data 
on this subject with most studies being set in developed countries.(14)(15)(16)(17)(26)(32) The 
placental findings were described based on the terminology used in the newer Amsterdam 
Classification(23) which is an attempt to standardize macro and micro sampling of placentas, 
whereas most studies in the literature have based their terminology on the Redline 
Classification.(17)(32)(35)(36) All neurodevelopmental follow up was done by a single examiner, and 
all placentas were re-reviewed by a single senior pathologist who was blinded to outcomes 
while in some studies only a subgroup were re-reviewed(14)(15)(17) . We had a comparative group 
while a few studies lacked this.(17)(32) One study excluded non-Caucasians, high risk 
pregnancies and HIV infected patients, all of which were included in this study.(16) 
 
The greatest limitation in this study is the small number of placentas available as a result of 
the poor submission rate of placentas for histology. Possible reasons for this include 
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knowledge gaps relating to appropriate placental submission and no available resources for 
placental pathology examination in the outborn population. The large proportion of outborn 
infants, some from far outlying areas, may have also made follow up at TBH difficult and 
contributed to the loss to follow up which limited the knowledge on their neurodevelopmental 
outcome. Cooling booklets and clinical notes were often not adequately completed which 
prevented patients from being eligible for this study.  The non-NE group was entirely inborn 
and consisted of a fair amount of twin studies which does add selection bias as those delivered 
at TBH mostly constitute high risk pregnancies who were referred for delivery at a tertiary 
institute. The non-NE group was not randomized and had no long-term neurodevelopmental 
follow up but this limitation is similar to that in other published studies. 
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6 Conclusion:  
VUE has been shown to be a significant risk factor for the development of NE and CP, similar 
to international studies.(14)(16)(17) VUE has a high recurrence rate and its effect on 
neurodevelopment in siblings has yet to be determined.(25)  As of yet there are no  treatment or 
preventative measures for VUE, thus increased surveillance of a subsequent pregnancy may 
be warranted given the high recurrence rate and association with an adverse 
neurodevelopmental outcome. Submission rates for placental pathology vary greatly but were 
unacceptably low in this study population.  
7 Recommendations:  
A larger study of this nature is needed to determine the true role of VUE and other placental 
lesions in our population.  For an optimal study to take place we will have to vastly improve 
placental submission rates. Possible ways of achieving this include: increased awareness in 
undergraduate and postgraduate training, improving visibility of guidelines for placental 
pathology submission and identifying a responsible healthcare practitioner involved in the 
delivery team who ensures accountability in deciding whether a placenta needs to be 
submitted at each delivery.  
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Appendix B: TBH cooling criteria based on the UK TOBY Cooling Register Clinician’s 
Handbook, section 2.1 
 
Infants with suspected birth asphyxia who have spontaneous respiration by 30 minutes of 
age should be assessed to determine whether they meet the criteria for cooling (Criteria A & 
B below), and should be discussed with the attending consultant. 
1 Criteria for considering treatment with cooling 
A.  Infants >36 completed weeks gestation with at least one of the following:  
 
 Apgar score of <7 at 10 minutes 
 Continued need for resuscitation, including endotracheal or mask ventilation, at 10 
minutes after birth 
 Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial 
or capillary pH <7.00) 
 Base Deficit ≥ 16 mmol/L in umbilical cord or any blood sample (arterial, venous or 
capillary) within 60 minutes of birth  
 
Infants that meet criteria A should be assessed for whether they meet the neurological 
abnormality entry criteria (B): 
B. Seizures or moderate to severe encephalopathy, consisting of:  
 
 Altered state of consciousness (reduced or absent response to stimulation) and 
 Abnormal tone (focal or general hypotonia, or flaccid) and 
 Abnormal primitive reflexes (weak or absent suck or Moro response) 
 
The severity of encephalopathy can be assessed using the table below. Infants should 
have abnormalities in at least 3 categories (e.g. tone, LOC, reflexes, autonomic 
function). 
 






Lethargic    Stupor or coma     
Spontaneous Activity Decreased Activity    No activity  
Posture Distal flexion, complete 
extension 
 Decerebrate  
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Tone Hypotonia (focal or 
general)   
 Flaccid  
Suck Weak  Absent   
Moro Incomplete    Absent  
Pupils Constricted  Deviated, dilated or non-
reactive 
 
Heart rate Bradycardia  Variable  
Respiration Periodic or shallow 
breathing   
 Apnoea    
 
 
 We use the Thompson HIE score now as that is what everyone is familiar with, & take a 
score of  7 as significant encephalopathy. 
2.  AEEG assessment 
The amplitude integrated EEG (aEEG) should ideally be recorded in all infants with suspected 
birth asphyxia, preferably before cooling is started. However, cooling need not be delayed 
until the aEEG is initiated. 
An apparently normal aEEG record may not necessarily guarantee a good outcome, and 
should therefore not be used to exclude infants from cooling if they have clear signs of 
moderate/severe encephalopathy on clinical grounds. 
IV anticonvulsant therapy may cause transient suppression of EEG activity. Ideally the aEEG 
should be commenced before administering anticonvulsant therapy. 
 
3.  When is cooling not appropriate? 
Cooling is not appropriate if: 
 The infant is likely to require surgery during the first 3 days after birth 
 There are other abnormalities indicative of poor long term outcome  
 
Ongoing cooling needs to be reviewed as it may not be appropriate if the infant appears 
moribund or has persisting extremely severe encephalopathy such that further treatment is 
likely to be futile, for example if the aEEG/EEG is isoelectric beyond 48 hours of age.  
Cooling may produce adverse respiratory or cardiovascular effects and should be used with 
caution in infants with an unstable respiratory or cardiovascular condition (e.g. PPHN). 
 
4.  When to start cooling? 
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Cooling should be started as soon as possible after resuscitation is completed, ideally within 
6 hours of birth.  
(Current evidence suggests that cooling is unlikely to be beneficial if started more than six to 
eight hours after birth.) 
5.  Protocol 
If the decision is made to treat with cooling, then the following steps should be followed: 
 
I.      Admission  
            Arrange admission to ICU if not already in ICU ASAP.  
            Switch off radiant/incubator heater - discontinue active warming. 
 
II.     On admission to neonatal ICU 
 
a.      I.       Switch off radiant/incubator heater - discontinue active warming  
                  (if not already done) 
                  ii.      Monitor rectal temperature (see nursing guidelines) 
                  iii.     Start CFM/aEEG  
 
b.    General management as per HIE guidelines.  
        
  
III.     Treatment with cooling 
a. Follow the Tecotherm system (or specific cooling system) guidelines                               
 (See separate sheet) 
i. Initial mattress temperature set to 28C – adjust according to response 
ii. Record time of starting cooling, initial temperature, and target date & time for 
stopping (72 hrs. from start). 
iii. NB: Make sure there are 22 pages in observation pack (excluding front 
reminder tick sheet). 
 
b. Aim for rectal temp of 33-34C (if whole body cooling) 
 
c. If baby shows signs of distress during cooling (e.g. relative tachycardia, shivering), 
sedation should be considered (if not already on sedation):  
 Phenobarbitone 10-20mg/kg, may be repeated up to 40mg/kg. OR 
 Lorazepam (Ativan) 0.05mg-0.1mg/kg/dose.  OR 
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 Morphine 50mcg/kg slow IV bolus over 10 minutes, then 50mcg/kg bolus 6 
hourly or infusion at 8mcg/kg/hr. Can double dose for +- 6 hours if still 
distressed, then review. 
 
IV.    Re-warming  
Cooling will be stopped 72 hours from when it was initiated. 
 
b. Rate of re-warming should not be more than 0.5C/hour 
 
c. If clinical condition deteriorates during re-warming 
i. Stop re-warming 
ii. Discuss with consultant 
 
 
V.       When to stop cooling? 
 
If a decision is made by the attending medical/nursing team to withdraw intensive care, 
cooling should be discontinued and, if time allows, the baby re-warmed before intensive 
care is withdrawn.  
 
NB.  Cooling & re-warming should be completed in ICU. 
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Appendix D: TBH Department of Anatomical Pathology Placenta Cluster Diagnosis 
Expanded Version 
 
Department of Anatomical Pathology 
Placenta Cluster Diagnosis Expanded Version: 
 
A) Maternal vascular Malperfusion: D8-00104 
 Criteria: 
 Small placenta (below the 10th centile for gestational age) 
 Cord <8mm in diameter at term 
 Infarction:  
o Any infarction in pre-term 
o >5% of non-peripheral parenchyma at term (inner 2/3) 
 Extensive infarction – microscopically. 
 Accelerated villous maturation 
 Distal villous hypoplasia 
 Decidual vasculopathy: mural hypertrophy / fibrinoid necrosis / acute atherosis / 
absence of spiral artery remodeling / arterial thrombosis / persistence of 
intramural endovascular trophoblast in the 3rd trimester. 
 Retroplacental haematoma 
 Increased syncytial knots (>33% of villi) 
o Uncertainty over: 
▪ Increase in perivillous fibrin 
▪ Increase in extravillous trophoblast 
▪ Placental pseudocysts 
▪ Chorionic laeve pseudocysts 
▪ Membranous decidual necrosis 
 Diagnosis: Minimum of 3 criteria (preferably 4) – MVM 
                    Need a small placenta (below 10th centile) with 2 (preferably 3) more features. 
                    If >1 but <3 or if ≥3 but placenta within normal ranges → placental compromise. 
G-0182 
                    If only 1 – isolated finding (e.g. decidual vasculopathy) – other causes) 
 
B) Foetal Vascular Malperfusion : D8-61540 
 Low Grade 
 High Grade:  
o >1 focus of avascular villi (total ≥45 villi over 3 sections or an average of 
>15 villi per section with or without thrombosis or 
o ≥2 occlusive  or non-occlusive thrombi in chorionic plate or major stem villi, 
or 
o multiple non-occlusive thrombi 
 Segmental: thrombotic occlusion of chorionic or stem villous vessels or stem 
vessel obliteration. 
 Global (indicating partially obstructed umbilical blood flow with 
▪ Venous ectasia 
▪ Intramural fibrin deposition in large vessels 
▪ Small foci (<5 villi per focus) of avascular villi or  
▪ Karyorrhectic villi. 
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C) Placental Insufficiency: D8-00122 
a. Maternal floor infarction 
i. Villi of the entire maternal floor are embedded in fibrin, to a thickness 
of at least 3mm, evident on at least one slide.  
b. Massive perivillous fibrin deposition disease 
i. Entrapment of at least 50% of the villi as seen on at least 1 slide. 
c. Massive histiocytic intevillositis 
d. Diffuse villous oedema 
e. Maturation arrest 
 
  Each entity is a diagnosis on its own. 
    
D) Placental Abruption: D8-0012A 
 Criteria need 2 major: 
 Clinical diagnosis of abruption placenta 
 Macroscopic abruption: >15% adherent retroplacental haematoma or indentation 
 Microscopic abruption – need at least 2 minor: 
o Retroplacental &/or retromembranous &/or marginal sinus haemorrhage 
o Dissection into the decidua and placental parenchyma 
o Overlying infarction/ crowding / agglutination / ischaemic damage to the 
syncytiotrophoblast. 
o Intravillous haemorrhage / congestion 
 
E)  Chorioamnionic Haemosiderosis (chronic/venous abruption): D6-31250 
 Iron deposits in the membranes, chorionic plate or decidua. 
 
F) Subacute Fetal Hypoxia with compensatory response: D8-720F8 
 Focal villous oedema 
 Chorangiosis (focal or diffuse) 
 Increase in fetal nucleated red blood cells 
 
G) Ascending Infection - chorioamnionitis:  D8-22202 
 Criteria: clusters of at least 5 neutrophils in the subchorionic layer. 
 Maternal Stage: 
o Stage 1 : acute subchorionitis or chorionitis 
o Stage 2 :  acute chorioamnionitis: polys extend into fibrous chorion and or 
amnion 
o Stage 3 : necrotizing chorioamnionitis: karyorrhexis of polys, amniocyte 
necrosis and/or amnion basement membrane hypereosinophlia 
 Maternal Grade: 
o Grade 1: not sever as defined 
o Grade 2: severe – confluent poly or with subchorionic microabscesses 
 Foetal Stage: 
o Stage 1: chorionic vasculitis or umbilical phlebitis 
o Stage 2: involvement of umbilical vein and one or more umbilical arteries 
o Stage 3: necrotizing funisitis 
 Foetal Grade: 
o Grade 1: not severe as defined 
o Grade 2: severe – near-confluent intramural poly with attenuation of 
vascular smooth muscle. 
 Association: 
o  minor component in intervillositis and  
o chorionic plate, stem villous or umbilical cord vascular thrombosis.  
 Intensity:  
o Confluent - continuous inflammatory infiltrate over an entire chorionic plate 
on a slide. 
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o Non-confluent – noncontinuous inflammatory infiltrate. 
o Microabscess formation: microabscess >20 cells in diameter – maternal 
response 
o Necrotizing funisitis – umbilical cord necrosis with acute inflammation. 
 
H) Haematogenous infection: R-1004D 
 Acute Villitis – neutrophils in the villi (major pattern) ± overspill into the intervillous 
space. Prominent numbers of neutrophils in the villous vessels. 
 Chronic villitis – lymphocytes, histiocytes &/or plasma cells in the villi ± villous lysis 
± overspill into the intervillous space. Characterized by focal areas of inflammation 
with monoculear cells and areas of fibrinoid necrosis in chorionic villi. 
o Lymphocytic villitis, Lymphoplasmacytic villitis, Lymphohistiocytic villitis, 
Histiocytic villitis and Granulomatous villitis. 
o Obliterative vasculopathy – when avascular villi are caused by inflammation 
(Infective or VUE) 
 Acute invervillositis – neutrophils in the intervillous space ± secondary overspill into 
the villi. 
 Intervillous micro abscesses are defined: when the acute intervillous inflammatory 
aggregate (intervillositis) starts to push apart neighbouring villi. 
 SNOMED: 
o CMV  : DE-32610 
o Syphilis  : DE-14505 
o Herpes : DE-32115 
o Chicken pox : DE-32390 
o Toxoplasma :  DE-51200 
o Parvovirus :  DE-30006 
 
I) Immunological damage: R-1004C   
a. Chronic villitis of unknown aetiology, VUE:  
i. High grade VUE - >10villi involved / focus, >1 focus on >1 slide. Either 
patchy or diffuse  
Either: 
 Patchy: >1 focus with one focus >10 villi in one or more slides. 
 Diffuse: >30% of distal villi are involved. 
 
ii. Low grade VUE - <10 villi involved / focus. >1 focus need.  
Either  
 focal: only 1 slide or  
 multifocal: >1 slide involved 
 
J) Small placenta, nos : F-03BED 
 
K) Within normal limits / no pathological diagnosis : M-00100 
  




A) Maternal vascular Malperfusion: D8-00104 
B) Foetal Vascular Malperfusion : D8-61540 
C) Placental Insufficiency: D8-00122 
D) Placental Abruption: D8-0012A 
E) Chorioamnionic Haemosiderosis (chronic/venous abruption): D6-31250 
F) Subacute Fetal Hypoxia with compensatory response: D8-720F8 
G) Ascending Infection - chorioamnionitis:  D8-22202 
H) Haematogenous infection: R-1004D 
a. CMV  : DE-32610 
b. Syphilis  : DE-14505 
c. Herpes : DE-32115 
d. Chicken pox : DE-32390 
e. Toxoplasma :  DE-51200 
f. Parvovirus :  DE-30006 
I) Immunological damage (Villitis VUE): R-1004C   
J) Small placenta, nos : F-03BED 
K) Within normal limits / no pathological diagnosis : M-00100 
L) Diabetic changes in a placenta: DB-61400 
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